Skip to content
  • COMPANY
    • OVERVIEW
    • LEADERSHIP
    • BOARD
    • TIMELINE
  • OUR NETWORK
    • FOUNDERS
    • CONSULTANTS
    • INVESTORS
  • OUR SCIENCE
    • INTRODUCTION
    • Mode of Action
    • SCIENCE LIBRARY
  • PIPELINE
    • OVERVIEW
    • PMD-OPTION study
    • OMT-28
  • NEWS & EVENTS
  • TEAM & CAREERS
  • LEGAL NOTICE
  • DISCLAIMER
  • DATA PROTECTION
Back to NEWS

Mitocon – Mitochondrial Disease Conference 2026

Meet us in Pisa, Italy, January 23–25

https://www.mitocon.it/sostegno-alla-ricerca/mito-conference/

Post navigation

OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
OMEICOS Therapeutics GmbH
Robert-Rössle-Strasse 10 (Building 79)
13125 Berlin, Germany
t +49 (0)30 9489 4810
f +49 (0)30 9489 4811
info@omeicos.com
OMEICOS Therapeutics, Inc.
c/o Remiges Biopharma Fund GP, Inc.
One Broadway, 14th Floor,
Cambridge, MA 02142, USA
info@omeicos.com
  • LEGAL NOTICE
  • DISCLAIMER
  • DATA PROTECTION
FOLLOW US
© 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.